Work

A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

DOI: 10.1080/21678421.2025.2515900

Authors: Amit Yeole, Laxmi Khanna, Maulik Doshi, Arvind Sharma, Pratik Uttarwar, Suyog Doshi, Rana Kaushik Kumar, N. Venkataramana, Deven Parmar

Institutions: Sir Ganga Ram Hospital, Sir Ganga Ram Hospital, Zydus Lifesciences Limited (India), Zydus Therapeutics Inc. (United States)

Language: English

Topic: Amyotrophic Lateral Sclerosis Research

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4411281113

FWCI: 4.51

Cites: 15

Cited by: 8

Related to: 10